MedTrace Logo

Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection

NCT06942624 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-04-24

No results posted yet for this study

Summary

This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient.

The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.

Conditions

  • Periprosthetic Joint Infection

Interventions

BIOLOGICAL

Phage Therapy

Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).

Sponsors & Collaborators

  • Cytophage Technologies Inc.

    collaborator UNKNOWN

  • Ottawa Hospital Research Institute

    collaborator OTHER

  • Orthopaedic Innovation Centre

    lead OTHER

Principal Investigators

  • David Hedden, MD · Concordia Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06942624 on ClinicalTrials.gov